IL151448A0 - Proteins - Google Patents

Proteins

Info

Publication number
IL151448A0
IL151448A0 IL15144801A IL15144801A IL151448A0 IL 151448 A0 IL151448 A0 IL 151448A0 IL 15144801 A IL15144801 A IL 15144801A IL 15144801 A IL15144801 A IL 15144801A IL 151448 A0 IL151448 A0 IL 151448A0
Authority
IL
Israel
Prior art keywords
breast cancer
proteins
prognosis
diagnosis
effectiveness
Prior art date
Application number
IL15144801A
Other languages
English (en)
Original Assignee
Oxford Glycosciences Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0004576.5A external-priority patent/GB0004576D0/en
Priority claimed from GB0031341A external-priority patent/GB0031341D0/en
Application filed by Oxford Glycosciences Uk Ltd filed Critical Oxford Glycosciences Uk Ltd
Publication of IL151448A0 publication Critical patent/IL151448A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IL15144801A 2000-02-25 2001-02-21 Proteins IL151448A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
GB0031341A GB0031341D0 (en) 2000-12-21 2000-12-21 Protein
PCT/GB2001/000748 WO2001062784A2 (en) 2000-02-25 2001-02-21 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
IL151448A0 true IL151448A0 (en) 2003-04-10

Family

ID=26243736

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15144801A IL151448A0 (en) 2000-02-25 2001-02-21 Proteins

Country Status (15)

Country Link
US (3) US20030130214A1 (xx)
EP (2) EP1259604A1 (xx)
JP (1) JP2003524017A (xx)
KR (1) KR100740761B1 (xx)
CN (1) CN100384875C (xx)
AT (1) ATE352311T1 (xx)
AU (3) AU2001233929C1 (xx)
BR (1) BR0108659A (xx)
CA (1) CA2399999A1 (xx)
DE (1) DE60126248T2 (xx)
ES (1) ES2279801T3 (xx)
HK (1) HK1056692A1 (xx)
IL (1) IL151448A0 (xx)
NZ (1) NZ520967A (xx)
WO (2) WO2001062784A2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
GB0125072D0 (en) * 2001-10-18 2001-12-12 Oxford Glycosciences Uk Ltd Protein
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003087834A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. High throughput analysis of recombinant proteins in multi-well plates
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
DE60332481D1 (de) * 2002-12-06 2010-06-17 Zhi Cheng Xiao Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
US20080254445A1 (en) * 2003-09-22 2008-10-16 Kyogo Itoh Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent
JP4794303B2 (ja) 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
KR101398079B1 (ko) * 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN104447975A (zh) * 2014-11-18 2015-03-25 深圳市人口和计划生育科学研究所 一种提取人肿瘤细胞膜蛋白的方法
US20180200331A1 (en) * 2015-07-10 2018-07-19 University Of Iowa Research Foundation Bst-2 as a therapeutic target and diagnostic marker for breast cancer growth and metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929575A4 (en) * 1996-08-23 2004-09-08 Human Genome Sciences Inc NEW HUMAN GROWTH FACTORS.
DE19813839A1 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe
BR0012069A (pt) * 1999-06-30 2002-08-27 Corixa Corp Composições e métodos para a terapia e diagnóstico de câncer pulmonar

Also Published As

Publication number Publication date
CN100384875C (zh) 2008-04-30
DE60126248T2 (de) 2007-07-05
CA2399999A1 (en) 2001-08-30
EP1257285B1 (en) 2007-01-24
WO2001062784A3 (en) 2002-01-31
HK1056692A1 (en) 2004-02-27
AU2001233929C1 (en) 2006-03-02
BR0108659A (pt) 2002-11-05
EP1259604A1 (en) 2002-11-27
KR100740761B1 (ko) 2007-07-19
US20030130214A1 (en) 2003-07-10
KR20030007440A (ko) 2003-01-23
CN1426307A (zh) 2003-06-25
AU2001233913A1 (en) 2001-09-03
US20030099662A1 (en) 2003-05-29
DE60126248D1 (de) 2007-03-15
EP1257285A2 (en) 2002-11-20
NZ520967A (en) 2004-04-30
AU3392901A (en) 2001-09-03
WO2001062914A1 (en) 2001-08-30
WO2001062784A2 (en) 2001-08-30
JP2003524017A (ja) 2003-08-12
US20070212368A1 (en) 2007-09-13
AU2001233929B2 (en) 2005-09-08
ATE352311T1 (de) 2007-02-15
ES2279801T3 (es) 2007-09-01

Similar Documents

Publication Publication Date Title
WO2003087831A3 (en) Proteins involved in breast cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
AU3392901A (en) Proteins
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
WO2007141280A3 (en) Proteins
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
AU2003217397A8 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
AU5947701A (en) Methods for identification, diagnosis, and treatment of breast cancer
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
WO2008026008A8 (en) Protein
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
WO2010026473A3 (en) Pta072 protein
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
NZ514691A (en) Method to type prion proteins
EP1438388A4 (en) IBC-1 (INVASIVE-1 BREAST CANCER), ONCOGEN PRESUME AMPLIFIED IN BREAST CANCER
WO2003020294A8 (de) Markierung der aromatase
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi